Contribution of a significant first-pass effect of dimethyl-4,4′- dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2′- dicarboxylate in the liver to its poor bioavailability in rats

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 9, 2009, Pages 1197-1203

  Yu, Kyung Ha ^a   Lee, Ye Rie ^a   Ahn, Sung Hoon ^a   Kim, Dae Duk ^a   Shim, Chang Koo ^a   Chung, Suk Jae ^a  

^a Seoul National University   (South Korea)

Author keywords

Caco 2 cell monolayer; Dimethyl 4,4 dimethoxy 5,6,5 ,6 dimethylene dioxybiphenyl 2,2 dicarboxylate; Intestinal absorption; Pharmacokinetics; Ussing chamber

Indexed keywords

DIMETHYL 4,4' DIMETHOXY 5,6,5',6' DIMETHYLENE DIOXYBIPHENYL 2,2' DICARBOXYLATE; SCHIZANDRIN; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; DICARBOXYLIC ACID; DIMETHYL-4,4'-DIMETHOXY-5,6,5',6'-DIMETHYLENE DIOXYBIPHENYL-2,2'-DICARBOXYLATE;

AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; FEMORAL VEIN; FIRST PASS EFFECT; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; LIVER; MALE; MEASUREMENT; NONHUMAN; OBSERVATIONAL STUDY; PYLORUS; RAT; VEIN; ANIMAL; BIOAVAILABILITY; BLOOD; CELL STRAIN CACO 2; INTESTINE; METABOLISM; PERMEABILITY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CACO-2 CELLS; DICARBOXYLIC ACIDS; HUMANS; INTESTINES; LIVER; MALE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 85047684277     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.09.0009     Document Type: Article

References (22)

1. Li XY. Bioactivity of neolignans from fructus Schizandrae. Mem Inst Oswaldo Cruz 1991; 86(Suppl. 2): 31-37.
2. Kim SH et al. Effect of biphenyl dimethyl dicarboxylate on chemical-induced hepatotoxicity. Korean J Toxicol 1995; 11: 181-185.
3. Fu T, Liu G. Protective effects of dimethyl-4,4′-dimethoxy-5,6, 5′,6′-dimethylene dioxybihenyl-2,2′-dicarboxylate (DDB) on damages of isolated rat hepatocytes induced by carbon tetrachloride and D-galactosamine. Biomed Environ Sci 1992; 5: 185-194.
4. Ahn YK, Kim JH. Preventive effects of diphenyl dimethyl dicarboxylate on the immunotoxicity of carbon tetrachloride in ICR mice. J Toxicol Sci 1993; 18: 185-195.
5. Kim SG et al. Inhibition of lipopolysaccharide-induced I-kappaBalpha degradation and tumor necrosis factor-alpha expression by dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybihenyl-2,2′-dicarboxylate (DDB): minor role in hepatic detoxifying enzyme expression. Liver 2000; 20: 319-329.
6. Kim SN et al. Effect of dimethyl-4,4′-dimethoxy-5,6, 5′,6′-dimethylene dioxybihenyl-2,2′-dicarboxylate (DDB) on chemical-induced liver injury. Biol Pharm Bull 1999; 22: 93-95.
7. Lee HS et al. Prospective, randomized, controlled trial with diphenyl-dimethyl-dicarboxylate in acute liver disease: the effect on lowering serum alanine aminotransferase levels. Korean J Intern Med 1991; 40: 172-178.
8. Gu SJ et al. Bioavailability studies on the preparations of biphenyl dimethyl dicarboxylate (DDB). Yao Xue Xue Bao 1990; 25: 215-219.
9. Bae SK et al. Pharmacokinetic interaction between oltipraz and dimethyl-4,4′-dimethoxy-5,6,5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate (DDB) after single intravenous and oral administration to rats. J Pharm Pharmacol 2003; 55: 1241-1249.
10. Hyun J, Chun IK. Dissolution characteristics of biphenyl dimethyl dicarboxylate fromsolid dispersions and permeation through rabbit duodenal mucosa. J Korean Pharm Sci 1994; 24: 57-65.
11. Baek MS et al. Metabolism of dimethyl-4,4′-dimethoxy-5,6, 5′,6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate (DDB) by human liver microsomes: characterization of metabolic pathways and of cytochrome P450 isoforms involved. Drug Metab Dispos 2001; 29: 381-388.
12. Hidalgo IJ et al. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-749.
13. Li H et al. The transport of a reversible proton pump antagonist, 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3, 4- tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across Caco-2 cell monolayers. Drug Metab Dispos 2001; 29: 54-59.
14. Maeng HJ et al. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci 2002; 91: 2614-2621.
15. Lee YR et al. Determination of dimethyl-4,4′-dimethoxy-5,6, 5′,6′-dimethylene dioxybiphenyl-2,2′-dicarboxylate in human serum by high performance liquid chromatography. Anal Lett 1999; 32: 945-954.
16. Cogburn JN et al. A model of human small intestinal absorptive cells, I. Transport barrier. Pharm Res 1991; 8: 210-216.
17. Chiu PY et al. Schisandrin B induced antioxidant response is partly mediated by cytochrome P-4502E1 catalyzed reaction in mouse liver. Mol Cell Biochem 2006; 293: 87-92.
18. Kim JY et al. Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4′-dimethoxy-5,6,5′, 6′-dimethylenedioxybiphenyl-2,2′-dicarboxylate. Drug Metab Dispos 2001; 29: 1555-1560.
19. Beubler E, Lembeck F. Inhibition of stimulated fluid secretion in the rat small and large intestine by opiate agonists. Naunyn Schmiedebergs Arch Pharmacol 1979; 306: 113-118.
20. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885.
21. DeSesso JM, Jacobson CF. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol 2001; 39: 209-228.
22. Madgula et al. Transport of Schisandra chinensis extract and its biologically-active constituents across Caco-2 cell monolayersan in-vitro model of intestinal transport. J Pharm Pharmacol 2008; 60: 363-370.